Who Paid My Doc
Amy McGhee
Hematology & Oncology Newark, DE Medical Doctor
NPI 1275976417 CMS profile 7221119
4701 Ogletown Stanton Rd, Suite 3400, Newark, DE 19713
General payments
$646
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Amy McGhee of Newark, DE is reported in the CMS Open Payments database as having received $646 across 34 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 30th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $217 | 6 | |
| 2023 | General | $16 | 1 | |
| 2022 | General | $77 | 5 | |
| 2021 | General | $80 | 5 | |
| 2020 | General | $256 | 17 |
Beside peers
- Amy McGhee
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Amy McGhee were reported at $217. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Amy McGhee | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $529 | $121–$2,516 | $163 |
| 2020 | $256 | $339 | $82–$2,213 | $114 |
| 2021 | $80 | $263 | $49–$1,965 | $132 |
| 2022 | $77 | $416 | $103–$2,395 | $149 |
| 2023 | $16 | $542 | $125–$2,646 | $160 |
| 2024 | $0 | $692 | $141–$3,008 | $164 |
| 2025 | $217 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
1,008
Drug cost
$1,406,410
Branded share of claims
11.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Verzenio Abemaciclib | Brand | 33 | $516,004 | |
| Ibrance Palbociclib | Brand | 19 | $301,316 | |
| Kisqali Ribociclib Succinate | Brand | 17 | $270,732 | |
| Tasigna Nilotinib Hcl | Brand | 13 | $261,852 | |
| Anastrozole | Generic | 592 | $25,162 | |
| Eliquis Apixaban | Brand | 38 | $24,078 | |
| Letrozole | Generic | 41 | $1,839 | |
| Tamoxifen Citrate | Generic | 36 | $1,662 | |
| Exemestane | Generic | 22 | $1,602 | |
| Ondansetron Hcl | Generic | 44 | $425 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 119 billing codesPaid by Medicare
$2,220,750
Medicare patients
549
Services billed
86,164
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 68% | |
| Arthritis | 52% | |
| Diabetes | 34% | |
| Chronic kidney disease | 28% | |
| Ischemic heart disease | 27% | |
| Depression | 26% | |
| Osteoporosis | 22% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 | Office | 12 | 4,680 | $185,965 |
| Injection, denosumab, 1 mg J0897 | Office | 29 | 3,840 | $80,140 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg J1454 | Office | 27 | 78 | $42,359 |
| Injection, ferric derisomaltose, 10 mg J1437 | Office | 21 | 2,200 | $35,048 |
| Injection, fulvestrant, 25 mg J9395 | Office | 13 | 1,150 | $7,105 |
| Injection, leucovorin calcium, per 50 mg J0640 | Office | 11 | 415 | $1,497 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 29 | 198 | $936 |
| Injection, fluorouracil, 500 mg J9190 | Office | 11 | 267 | $624 |
| Injection, carboplatin, 50 mg J9045 | Office | 15 | 227 | $624 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 18 | 330 | $245 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
34 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Hematology & Oncology in Delaware
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Delaware
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.